Trial Profile
89Zirconium-labeled Pembrolizumab as Predictive Imaging Biomarker of Response and Toxicity in Pembrolizumab Treated Patients With Non-small-cell Lung Cancer - a Feasibility Study
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 13 May 2022
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Diagnostic use
- 10 Sep 2019 Results assessing tumour uptake and biodistribution of 89Zr-labelleb pembrolizumab in patients with metastatic non-small cell lung cancer presented at the 20th World Conference on Lung Cancer
- 02 Mar 2017 New trial record